Where does Nucorion Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Nucorion Pharmaceuticals, Inc. ranks #32,690 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Nucorion Pharmaceuticals, Inc. hold?

Nucorion Pharmaceuticals, Inc. holds 8 US utility patents granted between 2016 and 2024, spanning 6 technology areas.

What is Nucorion Pharmaceuticals, Inc.'s Innovation Score?

Nucorion Pharmaceuticals, Inc. has an Innovation Score of 51.3 out of 100 (top 12% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Nucorion Pharmaceuticals, Inc. focus on?

Nucorion Pharmaceuticals, Inc.'s top technology area is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids) with 8 patents, ranking #116 of 896 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Nucorion Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Nucorion Pharmaceuticals, Inc.'s recent grant velocity is -40% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Nucorion Pharmaceuticals, Inc.'s patents?

Nucorion Pharmaceuticals, Inc.'s patents average 25.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Nucorion Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Nucorion Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 8 granted patents across 6 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nucorion ranks #32,690 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 6 technology areas.

#32,690
of 49,997 US assignees by volume: Top 12%
by Innovation Score (51.3/100): 25.6
avg claims per patent: -40%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R32690 · US Corporation #32,690 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #32,690/49,997
PHOTO-FINISH NPS Pharmaceuticals
CPC-NARROW C07H · 6 areas
INNOV-PAR 51.3/100
CLAIMS-DENSE 25.6 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -40% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: NPS Pharmaceuticals, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nucorion’s 51.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (15%) Velocity 20.0 pts (39%) Breadth 8.7 pts (17%) Claim depth 15.0 pts (29%)

Qualcomm Incorporated · highest

85
Nucorion Pharmaceuti… · this assignee

51
3D Lighting… · lowest

7

What this shows Nucorion's Innovation Score is 51.3/100 (top 12% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nucorion?

Each dot is one of Nucorion’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nucorion’s own 25.6 claims/patent is ABOVE the 11.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Nucorion vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nucorion's grants concentrate

Nucorion Pharmaceuticals, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids). Peak complete grant year is 2018 (2 grants) versus a trough of 1 in 2016. By volume, Nucorion sits between NPS Pharmaceuticals, Inc. and Numares AG.

Nucorion's three-year grant acceleration

Nucorion Pharmaceuticals, Inc. shows 3 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

NPS Pharmaceutica…

8
NRG Innovations

8
Nrtv Collab

8
Ntech Properties

8
Nueon

8
Nufarm Autralia

8
Nugen

8
Numares

8
Nucorion Pharmace… ◀

8

What this shows Nucorion holds 8 patents at rank #32,624, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Nucorion

By rank, the assignees closest to #32,624 in granted patent volume.

Leaders in C07H (Sugars)

Other assignees with the most granted patents in Nucorion's primary technology class.

Nucorion's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 12% higher than 88% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Nucorion Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	12.5%
2017	1	12.5%
2018	2	25.0%
2019	1	12.5%
2022	1	12.5%
2024	2	25.0%

Which technologies does Nucorion Pharmaceuticals, Inc. patent most?

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 8

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

Y02A - Technologies FOR Adaptation TO Climate Change 5

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

C07D - Heterocyclic Compounds 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Nucorion Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Nucorion Pharmaceuticals, Inc.'s lead technology class is C07H (SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids), 100% of its portfolio - see every assignee active in that class. Explore C07H
Ranked #32,690 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Nucorion Pharmaceuticals, Inc. against NPS Pharmaceuticals, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.